Clinical and Translational Cancer Control Research Training Program

摘要 这是临床和转化癌症控制研究培训计划的第三次竞争性更新 （CCRTP）R25 T，过渡到T32机制，由加里莫罗，博士，MS和米歇尔Janelsins领导， 罗切斯特大学（UR）哲学博士、公共卫生硕士。为期2至3年的CCRTP的主要目的是提供MD 和博士生的工具和必要的经验，以建立职业生涯作为杰出的独立 癌症控制研究的研究人员。该计划填补了培训下一代癌症的未满足需求 控制调查员。随着癌症治疗方法的改进提高了存活率， 幸存者和计数;这些幸存者继续经历持续的副作用，对质量产生负面影响 生命因此，更需要更好地了解癌症的许多使人衰弱的副作用 治疗和发展干预措施。该方案结合了教学和“动手”研究培训活动。 博士Janelsins是CCRTP的前毕业生，于2018年正式加入Morrow博士担任MPI，以增强 CCRTP的转化科学部分，与Morrow博士在临床试验方面的专业知识协同作用。 例如，最近的一些受训人员侧重于干预效果的生物机制， 减轻副作用，或了解生物，医学和心理风险因素，为那些谁可能发展 副作用. Morrow博士和Janelsins博士与21位多学科、杰出、经验丰富的R 01- 来自12个学术部门的资助导师和3名获得NCI K奖的初级导师，以及 来自NCI资助的社区肿瘤学研究计划（NCORP）研究基地的基础设施支持， UR临床和转化科学研究所（CTSI）等，以及无与伦比的机构 支持利用专门知识进行和发表独立分析并发展自己的分析 独立的临床和转化研究项目。这些研究经验得到了补充， 完成科学硕士（MS或MPH）学位，专注于临床调查，流行病学， 转化研究、健康服务或数据科学。在过去的5个班级中，有82名申请者（50名男性/32名 女性，18名医学博士/63名博士，8名少数民族）进行了评估; 27名被邀请进行现场访谈，其中15名 16名获得职位的人被接受，其中包括5名少数族裔申请人。他们生产了145种独特的 他撰写了多篇论文，获得了多项杰出研究奖，并获得了410万美元的研究经费。到 截至目前，完成该项目（过去15年）的31名学员中有29人获得了终身教职 职位，并实现了6300万美元的独立资金，包括25个R-赠款。在我们整个 从历史上看，我们招募了大约50%的妇女和30%的少数民族学员。大部分（94%）学员 仍在学术癌症研究为重点的职业生涯在助理（15），副（11），和全（3）教授 一些人还成为癌症中心主要项目的领导者或主任。我们的下一次续约 我们将继续在这一成功势头的基础上再接再厉。

ABSTRACT This is a third competing renewal of the Clinical and Translational Cancer Control Research Training Program (CCRTP) R25T, transitioning into the T32 mechanism, led by Gary Morrow, PhD, MS, and Michelle Janelsins, PhD, MPH, of the University of Rochester (UR). The primary aim of the 2- to 3-year CCRTP is to provide MD and PhD trainees with the tools and experiences necessary to establish careers as outstanding independent investigators in cancer control research. This program fills an unmet need to train the next generation of cancer control investigators. As improvements in cancer treatments increase survival rates, there are 20 million cancer survivors and counting; these survivors continue to experience ongoing side effects that negatively impact quality of life. Thus, there is a greater need to better understand the numerous debilitating side effects of cancer treatment and develop interventions. The program combines didactic and “hands-on” research training activities. Dr. Janelsins, a former graduate of the CCRTP, formally joined Dr. Morrow as MPI in 2018 to enhance the translational science component of the CCRTP, providing synergy with Dr. Morrow’s expertise in clinical trials. For example, a number of recent trainees have focused on biologic mechanisms of intervention effects to alleviate side effects, or understanding biologic, medical, and psychologic risk factors for those who may develop side effects. Dr. Morrow and Dr. Janelsins are joined by 21 multidisciplinary, outstanding, experienced R01- funded mentors and 3 junior mentors with NCI K Awards from 12 academic departments, and exceptional infrastructure support from the NCI-funded Community Oncology Research Program (NCORP) Research Base, the UR Clinical and Translational Sciences Institute (CTSI), among others, as well as unparalleled institutional support from which to draw upon expertise to conduct and publish independent analyses and develop their own independent clinical and translational research projects. These research experiences are complemented by completion of a Master of Science (MS or MPH) degree focused in clinical investigation, epidemiology, translational research, health services, or data science. For our last 5 classes, 82 applicants (50 males/32 females, 18 MD/63 PhD, 8 minority) have been evaluated; 27 were invited for on-site interviews and 15 of the 16 who were offered positions accepted, including 5 minority applicants. They have produced 145 unique manuscripts, obtained several outstanding research awards, and earned $4.1 million in research funding. To date, 29 of the 31 trainees who have completed the program (last 15 years) have obtained tenure-track academic positions, and achieved a total of $63 million in independent funding, including 25 R-grants. Throughout our history, we have recruited approximately 50% women and 30% minority trainees. A majority (94%) of our trainees are still in academic cancer research-focused careers at Assistant (15), Associate (11), and Full (3) Professor level; some have also become leaders or directors of major programs within cancer centers. Our next renewal will continue to build upon this momentum of success.